Nichiban Cuts Full-Year Forecast on Weak Demand for Core Healthcare Products

Nichiban Co., Ltd. ( (JP:4218) ) just unveiled an update.

Nichiban has cut its full-year consolidated forecast for the fiscal year ending March 31, 2026, lowering projected net sales from ¥51.5 billion to ¥50.0 billion and trimming operating profit from ¥3.0 billion to ¥2.2 billion, with profit attributable to owners of parent now seen at ¥1.4 billion versus ¥2.0 billion. The revisions imply declines of roughly 27% in operating profit and 30% in bottom-line profit versus the prior outlook, also placing earnings below the previous year’s levels.

The downgrade reflects weaker-than-expected sales of key products, as the ROIHI pain relief patch line suffered from shifts in consumer behavior and more diversified purchasing among inbound tourists. In addition, demand for premium first-aid bandages, which usually strengthens during colder months, has been dampened by lingering summer heat and milder winters in Japan, pressuring profitability and signaling a tougher operating environment for Nichiban in the near term.

The most recent analyst rating on (JP:4218) stock is a Hold with a Yen2101.00 price target. To see the full list of analyst forecasts on Nichiban Co., Ltd. stock, see the JP:4218 Stock Forecast page.

More about Nichiban Co., Ltd.

Nichiban Co., Ltd., listed on the TSE Prime, operates in the healthcare and consumer products sector, with a focus on adhesive-based goods such as pain relief anti-inflammatory patches and high-function first-aid bandages. Its core products include the ROIHI series patches and CARELEA VES and AKAGIRE HOGO BAN bandages, which are sensitive to seasonal demand and inbound tourist purchasing trends.

Average Trading Volume: 17,825

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen41.07B

For detailed information about 4218 stock, go to TipRanks’ Stock Analysis page.